Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GSK2336805

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
JNJ‐56914845 (GSK2336805) is a hepatitis C virus nonstructural protein 5A inhibitor under development for the treatment of… Expand
2014
2014
GSK2336805 is a HCV NS5A inhibitor for chronic hepatitis C (CHC). In a prior Phase I study, GSK2336805 was well tolerated and had… Expand
2014
2014
This Phase I, randomized, open‐label study evaluated the gastric pH‐altering effects of omeprazole, a proton pump inhibitor, and… Expand
2013
2013
ABSTRACT GSK2336805 is an orally bioavailable hepatitis C virus (HCV) inhibitor working through an NS5A-mediated mechanism. This… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
2013
2013
ABSTRACT GSK2336805 is an inhibitor of hepatitis C virus (HCV) with picomolar activity on the standard genotype 1a, 1b, and 2a… Expand
  • table 1
  • table 3
  • table 2
  • figure 1
  • figure 2
2013
2013
ABSTRACT GSK2336805 is a hepatitis C virus NS5A inhibitor in clinical development for the treatment of chronic hepatitis C virus… Expand
  • table 1
  • table 2
2011
2011
Results: GSK2336805 has EC50 values of 44 pM, 8 pM and 54 pM on genotype 1a, 1b and 2a (JFH-1) replicons, respectively and 63 pM… Expand